首页> 美国卫生研究院文献>Current Therapeutic Research Clinical and Experimental >Effectiveness of bromocriptine monotherapy or combination treatment with clomiphene for infertility in women with galactorrhea and normal prolactin: A systematic review and meta-analysis
【2h】

Effectiveness of bromocriptine monotherapy or combination treatment with clomiphene for infertility in women with galactorrhea and normal prolactin: A systematic review and meta-analysis

机译:溴隐亭单药或克罗米芬联合治疗对溢乳和泌乳素正常的女性不育的有效性:系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Among women with unexplained infertility, 28% to 55% of patients with galactorrhea are normoprolactinemic. Bromocriptine, a common treatment for infertile women with hyperprolactinemia, has been used in the treatment of unexplained subfertility in women with galactorrhea and normal prolactin; however, its effectiveness and safety profile have never been determined.>Objective: The aim of this study was to determine the relative effectiveness and safety profile of bromocriptine monotherapy or as an adjunct to clomiphene citrate in women with galactorrhea and normal prolactin levels.>Methods: We conducted a search of the Cochrane Subfertility Review Group specialized register of controlled trials (March 2010), CENTRAL (The Cochrane Library, Issue 3, 2010), MEDLINE (1950–March 2010), EMBASE (1980–March 2010), and the China Biological Medicine Database (inception to March 2010) for relevant randomized controlled trials (RCTs) using the following terms: controlled, randomized, blinded, clinical trials, humans, galactorrhea, prolactin, bromocriptine, infertility, and subfertility. Additionally, reference lists of identified articles were searched for relevant articles.>Results: Of the 8 studies identified, 5 were excluded after full-text review for the following reasons: lack of a placebo group (2); difference in cointerventions (1); difference in end points (1); and systematic review (1). Therefore, 3 RCTs were included in this review. Bromocriptine administered in combination with clomiphene was found to be associated with a higher accumulative pregnancy rate compared with clomiphene monotherapy (fixed odds ratio [OR], 5.33; 95% CI, 2.62–10.88), and a lower miscarriage rate (fixed OR, 0.20; 95% CI, 0.05–0.76). Only 1 trial reported live birth as an outcome, and multiple pregnancy rates were poorly reported. Patient-reported adverse effects were mentioned in the studies, but reports were often incomplete.>Conclusions: This review suggests the effectiveness of bromocriptine with clomiphene for infertility in women with galactorrhea and normal prolactin levels. Further RCTs of adequate power and of high methodologic quality are required to confirm these findings.
机译:>背景:在原因不明的女性中,溢乳病患者中有28%至55%的溢乳患者。溴隐亭是高催乳素血症不孕妇女的常见治疗方法,已被用于治疗溢乳病和泌乳素正常的妇女的不明原因的不孕症。 >目的:该研究的目的是确定溴隐亭单药或作为柠檬酸克罗米芬的辅助药物在溢乳和溢乳中的相对有效性和安全性。正常泌乳素水平。>方法:我们搜索了Cochrane亚生育力审查小组的专门对照试验登记册(2010年3月),CENTRAL(Cochrane图书馆,2010年第3期),MEDLINE(1950年3月) (2010年),EMBASE(1980年-2010年3月)和中国生物医学数据库(从2010年3月开始),使用以下术语进行相关的随机对照试验(RCT):对照,随机,盲法,临床试验,人类,溢乳,催乳素,溴隐亭,不孕和亚生育。 >结果:在确定的8项研究中,全文审查后排除了5项研究,其原因如下:缺乏安慰剂组(2);缺乏安慰剂组(3)。共同干预的差异(1);端点差异(1);和系统的审查(1)。因此,本评价纳入了3个RCT。与克罗米芬单药治疗相比,溴隐亭与克罗米芬联合给药具有更高的累积妊娠率(固定比值比[OR],5.33; 95%CI,2.62-10.88)和较低的流产率(固定OR,0.20) ; 95%CI,0.05-0.76)。只有1项试验报告了活产作为结果,而不良妊娠率却很少报道。研究中提到了患者报告的不良反应,但报告往往不完整。>结论:该评价表明溴隐亭与克罗米芬对溢乳和泌乳素水平正常的女性不育的有效性。需要进一步的具有足够能力和较高方法学质量的RCT来证实这些发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号